Corriente Advisors, LLC Cue Biopharma, Inc. Transaction History

Corriente Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$10.86 - $17.85 $10.3 Million - $16.9 Million	-948,389 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$10.06 - $15.3 $5.42 Million - $8.24 Million	-538,597 Reduced 36.22%	948,389 $13.8 Million
Q2 2021 Aug 16, 2021	SELL	$10.9 - $14.53 $11.6 Million - $15.4 Million	-1,062,045 Reduced 41.66%	1,486,986 $17.3 Million
Q1 2021 May 18, 2021	BUY	$11.2 - $16.09 $7.1 Million - $10.2 Million	633,812 Added 33.09%	2,549,031 $31.1 Million
Q4 2020 Feb 16, 2021	BUY	$11.12 - $16.4 $5.31 Million - $7.84 Million	477,774 Added 33.24%	1,915,219 $24 Million
Q3 2020 Nov 03, 2020	BUY	$15.05 - $23.54 $11.7 Million - $18.3 Million	777,458 Added 117.8%	1,437,445 $21.6 Million
Q2 2020 Aug 14, 2020	SELL	$12.7 - $30.73 $2.03 Million - $4.92 Million	-160,013 Reduced 19.51%	659,987 $16.2 Million
Q1 2020 May 18, 2020	BUY	$9.85 - $22.27 $5.27 Million - $11.9 Million	535,000 Added 187.72%	820,000 $11.6 Million
Q4 2019 Feb 14, 2020	BUY	$7.06 - $17.47 $2.01 Million - $4.98 Million	285,000 New	285,000 $4.52 Million

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $37.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Corriente Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Corriente Advisors, LLC with notifications on news.